{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T21:10:39Z","timestamp":1760044239961},"reference-count":55,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2018,4,2]],"date-time":"2018-04-02T00:00:00Z","timestamp":1522627200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Rheumatol Rep"],"published-print":{"date-parts":[[2018,5]]},"DOI":"10.1007\/s11926-018-0736-2","type":"journal-article","created":{"date-parts":[[2018,4,2]],"date-time":"2018-04-02T04:58:16Z","timestamp":1522645096000},"update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Eosinophilic Granulomatosis With Polyangiitis: Newer Therapies"],"prefix":"10.1007","volume":"20","author":[{"given":"Erika P.","family":"Navarro-Mendoza","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gabriel J.","family":"Tob\u00f3n","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,4,2]]},"reference":[{"key":"736_CR1","first-page":"1","volume":"65","author":"L Guillevin","year":"2013","unstructured":"\u2022\u2022 Guillevin L, Hagen EC, Hoffman GS, Jayne DR, Kallenberg CGM, Lamprecht P. 2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. Arthritis Rheum. 2013;65:1\u201311. The current consensus is achieved to describe clinical, radiological, and histological aspects useful in daily practice.","journal-title":"Arthritis Rheum"},{"key":"736_CR2","doi-asserted-by":"publisher","first-page":"2926","DOI":"10.1002\/art.21250","volume":"52","author":"RA Sinico","year":"2005","unstructured":"Sinico RA, Di Toma L, Maggiore U, Bottero P, Radice A, Tosoni C, et al. Prevalence and clinical significance of antineutrophil cytoplasmic antibodies in Churg-Strauss syndrome. Arthritis Rheum. 2005;52:2926\u201335.","journal-title":"Arthritis Rheum"},{"key":"736_CR3","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1016\/j.jaci.2012.02.019","volume":"130","author":"P Valent","year":"2012","unstructured":"Valent P, Klion AD, Horny H, Roufosse F, Gotlib J. Contemporary consensus proposal on criteria and classification of eosinophilic disorders and related syndromes. J Allergy Clin Immunol. 2012;130:607\u201312.e9.","journal-title":"J Allergy Clin Immunol"},{"key":"736_CR4","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/j.berh.2004.11.006","volume":"19","author":"RA Watts","year":"2005","unstructured":"Watts RA, Lane S. What is known about the epidemiology of the vasculitides? Best Pract Res Clin Rheumatol. 2005;19:191\u2013207.","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"736_CR5","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1111\/all.12088","volume":"68","author":"A Vaglio","year":"2013","unstructured":"Vaglio A, Buzio C, Zwerina J. Eosinophilic granulomatosis with polyangiitis (Churg\u2013Strauss): state of the art. Allergy. 2013;68:261\u201373.","journal-title":"Allergy"},{"key":"736_CR6","first-page":"277","volume":"27","author":"J Churg","year":"1951","unstructured":"Churg J, Strauss L. Allergic granulomatosis, allergic angiitis, and periarteritis nodosa. Am J Pathol. 1951;27:277\u2013301.","journal-title":"Am J Pathol"},{"key":"736_CR7","doi-asserted-by":"publisher","first-page":"1010","DOI":"10.1093\/clinids\/20.4.1010","volume":"20","author":"T Somer","year":"1995","unstructured":"Somer T, Finefold SM. Vasculitides associated with infections, immunization, and antimicrobial drugs. Clin Infect Dis. 1995;20:1010\u201336.","journal-title":"Clin Infect Dis"},{"key":"736_CR8","doi-asserted-by":"publisher","first-page":"3159","DOI":"10.1002\/art.22834","volume":"56","author":"A Vaglio","year":"2007","unstructured":"Vaglio A, Martorana D, Maggiore U, Grasselli C, Zanetti A, Pesci A, et al. HLA\u2013DRB4 as a genetic risk factor for Churg\u2013Strauss syndrome. Arthritis Rheum. 2007;56:3159\u201366.","journal-title":"Arthritis Rheum"},{"key":"736_CR9","first-page":"S23","volume":"29","author":"B Jakiela","year":"2011","unstructured":"Jakiela B, Sanak M, Szczeklik W, Sokolowska B, Plutecka H, Mastalerz L, et al. Both Th2 and Th17 responses are involved in the pathogenesis of Churg\u2013Strauss syndrome. Clin Exp Rheumatol. 2011;29:S23\u201334.","journal-title":"Clin Exp Rheumatol"},{"key":"736_CR10","first-page":"62","volume":"28","author":"C Schneeweis","year":"2010","unstructured":"Schneeweis C, Rafalowicz M, Feist E, Buttgereit F, Rudolph PE, Burmester GR, et al. Increased levels of BLyS and sVCAM-1 in anti-neutrophil cytoplasmatic antibody (ANCA)-associated vasculitides (AAV). Clin Exp Rheumatol. 2010;28:62\u20136.","journal-title":"Clin Exp Rheumatol"},{"key":"736_CR11","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/j.jaut.2014.01.018","volume":"48-49","author":"L Mouthon","year":"2014","unstructured":"Mouthon L, Dunoque B, Guillevin L. Diagnosis and classification of eosinophilic granulomatosis with polyangiitis (formerly named Churg-Strauss syndrome). J Autoimmun. 2014;48-49:99\u2013103.","journal-title":"J Autoimmun"},{"key":"736_CR12","doi-asserted-by":"publisher","first-page":"1887","DOI":"10.1093\/rheumatology\/kes171","volume":"51","author":"B Jakiela","year":"2012","unstructured":"\u2022 Jakiela B, Szczeklik W, Plutecka H, Sokolowska B, Mastalerz L, Sanak M, et al. Increased production of IL-5 and dominant Th2-type response in airways of Churg-Strauss syndrome patients. Rheumatology (Oxford). 2012;51:1887\u201393. This paper demonstrates the role of Th2 and Il5 in the pathogenesis of EGPA.","journal-title":"Rheumatology (Oxford)"},{"key":"736_CR13","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1002\/art.1780370206","volume":"37","author":"JC Jennette","year":"1994","unstructured":"\u2022\u2022 Jennette JC, Falk RJ, Andrassy K, Bacon PA, Churg J, Gross WL, et al. Nomenclature of systemic vasculitides: proposal of an international consensus conference. Arthritis Rheum. 1994;37:187\u201392. Describes the consensus of the Chapel Hill nomenclature for systemic vasculitis.","journal-title":"Arthritis Rheum"},{"key":"736_CR14","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1016\/S0889-857X(21)00479-8","volume":"21","author":"F Lhote","year":"1995","unstructured":"Lhote F, Guillevin L. Polyarteritis nodosa, microscopic polyangiitis, and Churg\u2013Strauss syndrome. Clinical aspects and treatment. Rheum Dis Clin N Am. 1995;21:911\u201347.","journal-title":"Rheum Dis Clin N Am"},{"key":"736_CR15","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1016\/j.autrev.2014.12.004","volume":"14","author":"A Greco","year":"2015","unstructured":"Greco A, Rizzo MI, De Virgilio A, Gallo A, Fusconi M, Ruoppolo G, et al. Churg-Strauss syndrome. Autoimmun Rev. 2015;14:341\u20138.","journal-title":"Autoimmun Rev"},{"key":"736_CR16","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1097\/00005792-198403000-00001","volume":"63","author":"JG Lanham","year":"1984","unstructured":"Lanham JG, Elkon KB, Pusey CD, Hughes GR. Systemic vasculitis with asthma and eosinophilia: a clinical approach to the Churg\u2013Strauss syndrome. Medicine (Baltimore). 1984;63:65\u201381.","journal-title":"Medicine (Baltimore)"},{"key":"736_CR17","doi-asserted-by":"publisher","first-page":"1094","DOI":"10.1002\/art.1780330806","volume":"33","author":"AT Masi","year":"1990","unstructured":"Masi AT, Hunder GG, Lie JT, Michel BA, Bloch DA, Arend WP, et al. The American College of Rheumatology 1990 criteria for the classification of Churg\u2013Strauss syndrome (allergic granulomatosis and angiitis). Arthritis Rheum. 1990;33:1094\u2013100.","journal-title":"Arthritis Rheum"},{"key":"736_CR18","doi-asserted-by":"publisher","first-page":"1004","DOI":"10.1136\/ard.2007.071936","volume":"67","author":"C Mukhtyar","year":"2008","unstructured":"Mukhtyar C, Flossmann O, Hellmich B, Bacon P, Cid M, Cohen-Tervaert JW, et al. Outcomes from studies of antineutrophil cytoplasm antibody associated vasculitis: a systematic review by the European League Against Rheumatism Systemic Vasculitis Task Force. Ann Rheum Dis. 2008;67:1004\u201310.","journal-title":"Ann Rheum Dis"},{"key":"736_CR19","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1097\/00005792-199601000-00003","volume":"75","author":"L Guillevin","year":"1996","unstructured":"Guillevin L, Lhote F, Gayraud M, Cohen P, Jarrousse B, Lortholary O, et al. Prognostic factors in polyarteritis nodosa and Churg\u2013Strauss Syndrome. A prospective study in 342 patients. Medicine (Baltimore). 1996;75:17\u201328.","journal-title":"Medicine (Baltimore)"},{"key":"736_CR20","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1016\/j.ejim.2015.04.022","volume":"26","author":"M Groh","year":"2015","unstructured":"Groh M, Pagnoux C, Baldini C, Bel E, Bottero P, Cottin V, et al. Eosinophilic granulomatosis with polyangiitis (Churg\u2013Strauss) (EGPA) Consensus Task Force recommendations for evaluation and management. Eur J Intern Med. 2015;26:545\u201353.","journal-title":"Eur J Intern Med"},{"key":"736_CR21","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1097\/BOR.0b013e3280119854","volume":"19","author":"C Pagnoux","year":"2007","unstructured":"Pagnoux C, Guilpain P, Guillevin L. Churg\u2013Strauss syndrome. Curr Opin Rheumatol. 2007;19:25\u201332.","journal-title":"Curr Opin Rheumatol"},{"key":"736_CR22","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.jaut.2013.03.003","volume":"43","author":"M Samson","year":"2013","unstructured":"Samson M, Pu\u00e9chal X, Devilliers H, Ribi C, Cohen P, Stern M, et al. Long-term outcomes of 118 patients with eosinophilic granulomatosis with polyangiitis (Churg\u2013Strauss syndrome) enrolled in two prospective trials. J Autoimmun. 2013;43:60\u20139.","journal-title":"J Autoimmun"},{"key":"736_CR23","doi-asserted-by":"publisher","first-page":"670","DOI":"10.7326\/0003-4819-150-10-200905190-00004","volume":"150","author":"K Groot De","year":"2009","unstructured":"De Groot K, Harper L, Jayne DR, Flores Suarez LF, Gregorini G, Gross WL, et al. Pulse versus daily oral cyclophosphamide for induction of remission in antineutrophil cytoplasmic antibody-associated vasculitis. Ann Intern Med. 2009;150:670\u201380.","journal-title":"Ann Intern Med"},{"key":"736_CR24","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1002\/art.39011","volume":"67","author":"C Pagnoux","year":"2015","unstructured":"Pagnoux C, Qu\u00e9m\u00e9neur T, Ninet J, Perrodeau E, Diot E, Kyndt X, et al. Treatment of systemic necrotizing vasculitides in patients aged sixty-five years or older: results of a multicenter, open-label, randomized controlled trial of corticosteroid and cyclophosphamide-based induction therapy. Arthritis Rheumatol. 2015;67:1117\u201327.","journal-title":"Arthritis Rheumatol"},{"key":"736_CR25","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1056\/NEJMoa020286","volume":"349","author":"D Jayne","year":"2003","unstructured":"Jayne D, Rasmussen N, Andrassy K, Bacon P, Tervaert JW, Dadonien\u00e9 J, et al. Randomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies. N Engl J Med. 2003;349:36\u201344.","journal-title":"N Engl J Med"},{"key":"736_CR26","doi-asserted-by":"publisher","first-page":"2790","DOI":"10.1056\/NEJMoa0802311","volume":"359","author":"C Pagnoux","year":"2008","unstructured":"Pagnoux C, Mahr A, Hamidou MA, Boffa JJ, Ruivard M, Ducroix JP, et al. Azathioprine or methotrexate maintenance for ANCA-associated vasculitis. N Engl J Med. 2008;359:2790\u2013803.","journal-title":"N Engl J Med"},{"key":"736_CR27","doi-asserted-by":"publisher","first-page":"1771","DOI":"10.1056\/NEJMoa1404231","volume":"371","author":"L Guillevin","year":"2014","unstructured":"Guillevin L, Pagnoux C, Karras A, Khouatra C, Auma\u00eetre O, Cohen P, et al. Rituximab versus azathioprine for maintenance in ANCA-associated vasculitis. N Engl J Med. 2014;371:1771\u201380.","journal-title":"N Engl J Med"},{"key":"736_CR28","doi-asserted-by":"publisher","first-page":"2175","DOI":"10.1002\/art.40205","volume":"69","author":"X Pu\u00e9chal","year":"2017","unstructured":"Pu\u00e9chal X, Pagnoux C, Baron G, French Vasculitis Study Group, et al. Adding azathioprine to remission-induction glucocorticoids for eosinophilic granulomatosis with polyangiitis (Churg-Strauss), microscopic polyangiitis, or polyarteritis nodosa without poor prognosis factors: a randomized, controlled trial. Arthritis Rheumatol. 2017;69:2175\u201386.","journal-title":"Arthritis Rheumatol"},{"key":"736_CR29","doi-asserted-by":"publisher","first-page":"e000449","DOI":"10.1136\/rmdopen-2017-000449","volume":"3","author":"M Yates","year":"2017","unstructured":"\u2022\u2022 Yates M, Watts R, Bajema I, Cid M, Crestani B, Hauser T, et al. Validation of the EULAR\/ERA-EDTA recommendations for the management of ANCA-associated vasculitis by disease content experts. RMD Open. 2017;3:e000449. This paper makes the EULAR\/ERA-EDTA treatment focus recommendations for EGPA patients based on level evidence.","journal-title":"RMD Open"},{"key":"736_CR30","doi-asserted-by":"publisher","first-page":"1649","DOI":"10.1136\/ard.2003.015453","volume":"63","author":"MG Danieli","year":"2004","unstructured":"Danieli MG, Cappelli M, Malcangi G, Logullo F, Salvi A, Danieli G. Long term effectiveness of intravenous immunoglobulin in Churg\u2013Strauss syndrome. Ann Rheum Dis. 2004;63:1649\u20135.","journal-title":"Ann Rheum Dis"},{"key":"736_CR31","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1056\/NEJMoa0909169","volume":"363","author":"RB Jones","year":"2010","unstructured":"Jones RB, Tervaert JW, Hauser T, Luqmani R, Morgan MD, Peh CA, et al. Rituximab versus cyclophosphamide in ANCA associated renal vasculitis. N Engl J Med. 2010;363:211\u201320.","journal-title":"N Engl J Med"},{"key":"736_CR32","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1056\/NEJMoa0909905","volume":"363","author":"JH Stone","year":"2010","unstructured":"Stone JH, Merkel PA, Spiera R, Seo P, Langford CA, Hoffman GS, et al. Rituximab versus cyclophosphamide for ANCA associated vasculitis. N Engl J Med. 2010;363:221\u201332.","journal-title":"N Engl J Med"},{"key":"736_CR33","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1056\/NEJMoa1213277","volume":"369","author":"U Specks","year":"2013","unstructured":"Specks U, Merkel PA, Seo P, Spiera R, Langford CA, Hoffman GS, et al. Efficacy of remission-induction regimens for ANCA associated vasculitis. N Engl J Med. 2013;369:417\u201327.","journal-title":"N Engl J Med"},{"key":"736_CR34","doi-asserted-by":"publisher","first-page":"R133","DOI":"10.1186\/ar4313","volume":"15","author":"J Thiel","year":"2013","unstructured":"Thiel J, H\u00e4ssler F, Salzer U, Voll RE, Venhoff N. Rituximab in the treatment of refractory or relapsing eosinophilic granulomatosis with polyangiitis (Churg\u2212Strauss syndrome). Arthritis Res Ther. 2013;15:R133.","journal-title":"Arthritis Res Ther"},{"key":"736_CR35","doi-asserted-by":"publisher","first-page":"1555","DOI":"10.1016\/j.jaip.2017.07.027","volume":"5","author":"J Thiel","year":"2017","unstructured":"Thiel J, Troilo A, Salzer U, Schleyer T, Halmschlag K, Rizzi M. Rituximab as induction therapy in eosinophilic granulomatosis with polyangiitis refractory to conventional immunosuppressive treatment: a 36-month follow-up analysis. J Allergy Clin Immunol Pract. 2017;5:1555\u201363.","journal-title":"J Allergy Clin Immunol Pract"},{"key":"736_CR36","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1136\/annrheumdis-2014-206095","volume":"75","author":"AJ Mohamad","year":"2016","unstructured":"Mohamad AJ, Hot A, Arndt F, Moosiq F, Guerry MJ, Amudala N, et al. Rituximab for the treatment of eosinophilic granulomatosis with polyangiitis (Churg-Strauss). Ann Rheum Dis. 2016;75:396\u2013401.","journal-title":"Ann Rheum Dis"},{"key":"736_CR37","doi-asserted-by":"publisher","first-page":"2159","DOI":"10.1007\/s10067-017-3780-9","volume":"36","author":"D Aguirre- Valencia","year":"2017","unstructured":"Aguirre- Valencia D, Posso-Osorio I, Bravo JC, Bonilla- Abad\u00eda F, Tob\u00f3n GJ, Ca\u00f1as CA. Sequential rituximab and omalizumab for the treatment of eosinophilic granulomatosis with polyangiitis (Churg-Strauss syndrome). Clin Rheumatol. 2017;36:2159\u201362.","journal-title":"Clin Rheumatol"},{"key":"736_CR38","doi-asserted-by":"publisher","first-page":"1493","DOI":"10.1016\/j.jaci.2006.02.028","volume":"117","author":"O Noga","year":"2006","unstructured":"Noga O, Hanf G, Brachmann I, Klucken AC, Kleine-Tebbe J, Rosseau S, et al. Effect of omalizumab treatment on peripheral eosinophil and T-lymphocyte function in patients with allergic asthma. J Allergy Clin Immunol. 2006;117:1493\u20139.","journal-title":"J Allergy Clin Immunol"},{"key":"736_CR39","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1159\/000103228","volume":"144","author":"P Giavina-Bianchi","year":"2007","unstructured":"Giavina-Bianchi P, Giavina-Bianchi M, Agondi R, Kalil J. Administration of anti-IgE to a Churg-Strauss syndrome patient. Int Arch Allergy Immunol. 2007;144:155\u20138.","journal-title":"Int Arch Allergy Immunol"},{"key":"736_CR40","doi-asserted-by":"publisher","first-page":"201","DOI":"10.3109\/02770903.2015.1081700","volume":"53","author":"A Detoraki","year":"2016","unstructured":"Detoraki A, Di Capua L, Varricchi G, Genovese A, Marone G, Spadaro G. Omalizumab in patients with eosinophilic granulomatosis with polyangiitis: a 36-month follow-up study. J Asthma. 2016;53:201\u20136.","journal-title":"J Asthma"},{"key":"736_CR41","doi-asserted-by":"publisher","first-page":"2274","DOI":"10.1002\/art.39663","volume":"68","author":"M Jachiet","year":"2016","unstructured":"\u2022 Jachiet M, Samson M, Cottin M, Kahn JE, Le Guenno G, Bonniaud P, et al. Anti-IgE monoclonal antibody (omalizumab) in refractory and relapsing eosinophilic granulomatosis with polyangiitis (Churg-Strauss). Arthritis Rheumatol. 2016;68:2274\u201382. This is the largest study which used omalizumab in EGPA patients.","journal-title":"Arthritis Rheumatol"},{"key":"736_CR42","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1016\/j.anai.2016.12.003","volume":"118","author":"S Nazir","year":"2017","unstructured":"Nazir S, Tachamo N, Fareedy SB, Khan MS, Lohani S. Omalizumab-associated eosinophilic granulomatosis with polyangiitis (Churg-Strauss syndrome). Ann Allergy Asthma Immunol. 2017;118:372\u20134.e1.","journal-title":"Ann Allergy Asthma Immunol"},{"key":"736_CR43","doi-asserted-by":"publisher","first-page":"129","DOI":"10.5152\/eurjrheum.2015.0086","volume":"2","author":"M Bek\u00e7iba\u015f\u0131","year":"2015","unstructured":"Bek\u00e7iba\u015f\u0131 M, Barut\u00e7u S, \u00c7elen MK, Dayan S, Ho\u015fo\u011flu S. Churg-Strauss syndrome occurring during omalizumab treatment. Eur J Rheumatol. 2015;2:129\u201330.","journal-title":"Eur J Rheumatol"},{"key":"736_CR44","first-page":"515","volume":"23","author":"C Cisneros","year":"2013","unstructured":"Cisneros C, Segrelles G, Herr\u00e1ez L, Gonzalez A, Gir\u00f3n R. Churg-Strauss syndrome in a patient treated with omalizumab. J Investig Allergol Clin Immunol. 2013;23:515\u20136.","journal-title":"J Investig Allergol Clin Immunol"},{"key":"736_CR45","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1378\/chest.08-2990","volume":"136","author":"ME Wechsler","year":"2009","unstructured":"Wechsler ME, Wong DA, Miller MK, Lawrence-Miyasaki L. Churg-Strauss syndrome in patients treated with omalizumab. Chest. 2009;136:507\u201318.","journal-title":"Chest"},{"key":"736_CR46","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1016\/j.ejim.2007.09.001","volume":"19","author":"X Pu\u00e9chal","year":"2008","unstructured":"Pu\u00e9chal X, Rivereau P, Vinchon F. Churg-Strauss syndrome associated with omalizumab. Eur J Intern Med. 2008;19:364\u20136.","journal-title":"Eur J Intern Med"},{"key":"736_CR47","doi-asserted-by":"publisher","first-page":"PA5091","DOI":"10.1183\/13993003.00536-2015","volume":"46","author":"GM Gauvreau","year":"2015","unstructured":"Gauvreau GM, Boulet LP, Leigh R, Cockcroft DW, Davis BE, Mayers I. QGE031 (ligelizumab) is more effective than omalizumab and placebo in inhibiting allergen-induced early asthmatic response: results from a predictive modeling study. Eur Respir J. 2015;46:PA5091.","journal-title":"Eur Respir J"},{"key":"736_CR48","doi-asserted-by":"publisher","first-page":"135","DOI":"10.3389\/fmed.2017.00135","volume":"4","author":"D Bagnasco","year":"2017","unstructured":"Bagnasco D, Ferrando M, Varricchhi G, Puggioni F, Passalacqua G, Canonica GW. Anti-interleukin 5 (iL-5) and iL-5Ra biological drugs: efficacy, safety, and future perspectives in severe eosinophilic asthma. Front Med (Lausanne). 2017;4:135.","journal-title":"Front Med (Lausanne)"},{"key":"736_CR49","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1016\/j.jaci.2009.10.014","volume":"125","author":"JE Kahn","year":"2010","unstructured":"Kahn JE, Grandpeix-Guyodo C, Marroun I, Catherinot E, Mellot F, Roufosse F, et al. Sustained response to mepolizumab in refractory Churg-Strauss syndrome. J Allergy Clin Immunol. 2010;125:267\u201370.","journal-title":"J Allergy Clin Immunol"},{"key":"736_CR50","doi-asserted-by":"publisher","first-page":"1336","DOI":"10.1016\/j.jaci.2010.03.028","volume":"125","author":"S Kim","year":"2010","unstructured":"Kim S, Marigowda G, Oren E, Israel E, Wechsler ME. Mepolizumab as a steroid sparing treatment option in patients with Churg\u2013Strauss syndrome. J Allergy Clin Immunol. 2010;125:1336\u201343.","journal-title":"J Allergy Clin Immunol"},{"key":"736_CR51","doi-asserted-by":"publisher","first-page":"341","DOI":"10.7326\/0003-4819-155-5-201109060-00026","volume":"155","author":"F Moosig","year":"2011","unstructured":"Moosig F, Gross WL, Herrmann K, Bremer JP, Hellmich B. Targeting interleukin-5 in refractory and relapsing Churg\u2013Strauss syndrome. Ann Intern Med. 2011;155:341\u20133.","journal-title":"Ann Intern Med"},{"key":"736_CR52","first-page":"S62","volume":"30","author":"K Herrmann","year":"2012","unstructured":"Herrmann K, Gross WL, Moosig F. Extended follow-up after stopping mepolizumab in relapsing\/refractory Churg-Strauss syndrome. Clin Exp Rheumatol. 2012;30:S62\u20135.","journal-title":"Clin Exp Rheumatol"},{"key":"736_CR53","doi-asserted-by":"publisher","first-page":"1921","DOI":"10.1056\/NEJMoa1702079","volume":"376","author":"ME Wechsler","year":"2017","unstructured":"\u2022\u2022 Wechsler ME, Akuthota P, Jayne D, Khoury P, Klion A, Langford CA, et al. Mepolizumab or placebo for eosinophilic granulomatosis with polyangiitis. N Engl J Med. 2017;376:1921\u201332. This is the first multicenter double-blind randomized clinical controlled trial that investigates remission in EGPA patient using mepolizumab.","journal-title":"N Engl J Med"},{"issue":"9","key":"736_CR54","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1038\/nrrheum.2017.117","volume":"13","author":"L Guillevin","year":"2017","unstructured":"Guillevin L. Vasculitis: mepolizumab for eosinophilic granulomatosis with polyangiitis. Nat Rev Rheumatol. 2017;13(9):518\u20139.","journal-title":"Nat Rev Rheumatol"},{"key":"736_CR55","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1056\/NEJMoa1314768","volume":"371","author":"L Beck","year":"2014","unstructured":"Beck L, Diamant T, Hamilton J, Graham N, Bieber T, Rocklin R, et al. Dupilumab in adults with moderate-to-severe atopic dermatitis. N Engl J Med. 2014;371:130\u20139.","journal-title":"N Engl J Med"}],"container-title":["Current Rheumatology Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11926-018-0736-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11926-018-0736-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11926-018-0736-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,17]],"date-time":"2022-08-17T18:21:05Z","timestamp":1660760465000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11926-018-0736-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,4,2]]},"references-count":55,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2018,5]]}},"alternative-id":["736"],"URL":"https:\/\/doi.org\/10.1007\/s11926-018-0736-2","relation":{},"ISSN":["1523-3774","1534-6307"],"issn-type":[{"value":"1523-3774","type":"print"},{"value":"1534-6307","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,4,2]]},"assertion":[{"value":"2 April 2018","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance With Ethical Standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article does not contain any studies with human or animal subjects performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}}],"article-number":"23"}}